126 related articles for article (PubMed ID: 18597648)
1. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers.
González I; Peñas-Lledó EM; Pérez B; Dorado P; Alvarez M; LLerena A
Pharmacogenomics; 2008 Jul; 9(7):833-40. PubMed ID: 18597648
[TBL] [Abstract][Full Text] [Related]
2. Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers.
Peñas-LLedó EM; Dorado P; Pacheco R; González I; LLerena A
Pharmacogenomics; 2009 Jul; 10(7):1111-20. PubMed ID: 19604084
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.
Llerena A; Dorado P; Ramírez R; González I; Alvarez M; Peñas-Lledó EM; Pérez B; Calzadilla LR
Pharmacogenomics J; 2012 Apr; 12(2):176-83. PubMed ID: 21135868
[TBL] [Abstract][Full Text] [Related]
4. [Study of debrisoquine hydroxylation polymorphism (CYP2D6) in the Cuban population compared to Spaniards].
González I; Pérez B; Alvarez M; Dorado P; Llerena A
Med Clin (Barc); 2007 May; 128(20):772-4. PubMed ID: 17568504
[TBL] [Abstract][Full Text] [Related]
5. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.
Llerena A; Edman G; Cobaleda J; Benítez J; Schalling D; Bertilsson L
Acta Psychiatr Scand; 1993 Jan; 87(1):23-8. PubMed ID: 8424321
[TBL] [Abstract][Full Text] [Related]
6. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A; Dorado P; Peñas-Lledó EM
Pharmacogenomics; 2009 Jan; 10(1):17-28. PubMed ID: 19102711
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
Dorado P; Peñas-Lledó EM; Llerena A
Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.
Llerena A; Dorado P; Ramírez R; Calzadilla LR; Peñas-Lledó E; Álvarez M; Naranjo ME; González I; Pérez B;
Pharmacogenomics; 2013 Dec; 14(16):1973-7. PubMed ID: 24279852
[TBL] [Abstract][Full Text] [Related]
10. Relationship between Type A and B personality and debrisoquine hydroxylation capacity.
Gan SH; Ismail R; Wan Adnan WA; Zulmi W; Kumaraswamy N; Larmie ET
Br J Clin Pharmacol; 2004 Jun; 57(6):785-9. PubMed ID: 15151524
[TBL] [Abstract][Full Text] [Related]
11. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
13. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
[TBL] [Abstract][Full Text] [Related]
14. No association between CYP2D6 polymorphisms and personality trait in Japanese.
Iwashima K; Yasui-Furukori N; Kaneda A; Saito M; Nakagami T; Sato Y; Kaneko S
Br J Clin Pharmacol; 2007 Jul; 64(1):96-9. PubMed ID: 17324244
[TBL] [Abstract][Full Text] [Related]
15. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
16. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
LLerena A; Herraíz AG; Cobaleda J; Johansson I; Dahl ML
Clin Pharmacol Ther; 1993 Dec; 54(6):606-11. PubMed ID: 7903915
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
18. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
19. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
LLerena A; Berecz R; de la Rubia A; Fernández-Salguero P; Dorado P
Ther Drug Monit; 2001 Dec; 23(6):616-20. PubMed ID: 11802093
[TBL] [Abstract][Full Text] [Related]
20. [Prevalence of ultraextensive drug metabolizers in Croatian population--long-PCR based detection of amplified CYP2D6 gene].
Bozina N; Tramisak I; Granić P; Puljević D; Stavljenić-Rukavina A
Lijec Vjesn; 2002; 124(3-4):63-6. PubMed ID: 18958918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
